Craig Crews in the News: First targeted protein degrader hits the clinic

Craig Crews was featured in Nature Medicine for his work on new therapeutics that harness cellular machinery to degrade targets are entering clinical trials, led by a PROTAC anticancer candidate developed by Arvinas.

For more on this story, please visit https://www.nature.com/articles/d41573-019-00043-6.